Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on DexCom DXCM in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $126.38, a high estimate of $150.00, and a low estimate of $100.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.6%.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of DexCom by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jayson Bedford | Raymond James | Raises | Strong Buy | $147.00 | $131.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $150.00 | $135.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $136.00 | $110.00 |
| Patrick Wood | Morgan Stanley | Raises | Equal-Weight | $122.00 | $101.00 |
| Patrick Wood | Morgan Stanley | Raises | Equal-Weight | $101.00 | $98.00 |
| Michael Weinstein | JP Morgan | Lowers | Overweight | $100.00 | $160.00 |
| Mike Kratky | Leerink Partners | Announces | Outperform | $110.00 | - |
| Mathew Blackman | Stifel | Lowers | Buy | $145.00 | $155.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DexCom. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DexCom compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.
Capture valuable insights into DexCom's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on DexCom analyst ratings.
Delving into DexCom's Background
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
DexCom: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: DexCom's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 26.69%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 12.38%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): DexCom's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.8%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: DexCom's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.2, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
